Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1891 1
1897 1
1919 1
1936 1
1945 1
1946 1
1947 2
1949 2
1951 1
1952 2
1953 4
1954 4
1955 6
1956 1
1957 4
1958 1
1959 3
1960 1
1961 2
1962 5
1963 8
1964 7
1965 11
1966 1
1967 1
1968 8
1969 6
1970 14
1971 11
1972 7
1973 6
1974 8
1975 3
1976 6
1977 8
1978 8
1979 10
1980 9
1981 16
1982 9
1983 12
1984 15
1985 14
1986 17
1987 14
1988 13
1989 19
1990 12
1991 13
1992 12
1993 16
1994 10
1995 14
1996 14
1997 4
1998 7
1999 8
2000 5
2001 10
2002 13
2003 6
2004 9
2005 21
2006 16
2007 16
2008 13
2009 17
2010 13
2011 17
2012 15
2013 14
2014 6
2015 8
2016 9
2017 2
2018 7
2019 8
2020 11
2021 11
2022 7
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

645 results

Results by year

Filters applied: . Clear all
Page 1
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. Fallah J, et al. Among authors: pierce wf. Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054. Clin Cancer Res. 2022. PMID: 35727604 Free PMC article.
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L. Dilawari A, et al. Among authors: pierce wf. Clin Cancer Res. 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. Clin Cancer Res. 2023. PMID: 37212825
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
Shah M, Osgood CL, Amatya AK, Fiero MH, Pierce WF, Nair A, Herz J, Robertson KJ, Mixter BD, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. Shah M, et al. Among authors: pierce wf. Clin Cancer Res. 2022 Dec 15;28(24):5249-5253. doi: 10.1158/1078-0432.CCR-22-1110. Clin Cancer Res. 2022. PMID: 35925043 Clinical Trial.
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. Fallah J, et al. Among authors: pierce wf. Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875. Clin Cancer Res. 2023. PMID: 36469000 Free PMC article. Clinical Trial.
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Narayan P, Osgood CL, Singh H, Chiu HJ, Ricks TK, Chiu Yuen Chow E, Qiu J, Song P, Yu J, Namuswe F, Guiterrez-Lugo M, Hou S, Pierce WF, Goldberg KB, Tang S, Amiri-Kordestani L, Theoret MR, Pazdur R, Beaver JA. Narayan P, et al. Among authors: pierce wf. Clin Cancer Res. 2021 Aug 15;27(16):4478-4485. doi: 10.1158/1078-0432.CCR-20-4557. Epub 2021 Mar 22. Clin Cancer Res. 2021. PMID: 33753456 Free PMC article. Clinical Trial.
Pediatric tone management.
Vadivelu S, Stratton A, Pierce W. Vadivelu S, et al. Among authors: pierce w. Phys Med Rehabil Clin N Am. 2015 Feb;26(1):69-78. doi: 10.1016/j.pmr.2014.09.008. Phys Med Rehabil Clin N Am. 2015. PMID: 25479780 Review.
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, Jafri S, Kalavar S, Kondratovich M, Jha P, Ghosh S, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. Narayan P, et al. Among authors: pierce wf. J Clin Oncol. 2023 Apr 10;41(11):2108-2116. doi: 10.1200/JCO.22.02447. Epub 2023 Feb 13. J Clin Oncol. 2023. PMID: 36780610 Clinical Trial.
Acquired Von Willebrand Syndrome and Blood Pump Design.
Rosenberg G, Siedlecki CA, Jhun CS, Weiss WJ, Manning K, Deutsch S, Pierce W. Rosenberg G, et al. Among authors: pierce w. Artif Organs. 2018 Dec;42(12):1119-1124. doi: 10.1111/aor.13291. Epub 2018 Oct 28. Artif Organs. 2018. PMID: 30370640 Review.
Doxorubicin-induced thymus senescence.
Sultana R, Di Domenico F, Tseng M, Cai J, Noel T, Chelvarajan RL, Pierce WD, Cini C, Bondada S, St Clair DK, Butterfield DA. Sultana R, et al. Among authors: pierce wd. J Proteome Res. 2010 Dec 3;9(12):6232-41. doi: 10.1021/pr100465m. Epub 2010 Nov 9. J Proteome Res. 2010. PMID: 20945937
Pharmacist readiness roles for emergency preparedness.
Pincock LL, Montello MJ, Tarosky MJ, Pierce WF, Edwards CW. Pincock LL, et al. Among authors: pierce wf. Am J Health Syst Pharm. 2011 Apr 1;68(7):620-3. doi: 10.2146/ajhp090659. Am J Health Syst Pharm. 2011. PMID: 21411804 Review. No abstract available.
645 results